Modern Pediatrics. Ukraine. (2022). 3(123): 80-84. doi 10.15574/SP.2022.123.80
Боярчук О. Р.
Тернопольский национальный медицинский университет имени И.Я. Горбачевского МЗ Украины

Для цитирования: Boyarchuk OR. (2022). Modern approaches to the treatment of congenital neutropenia. Modern Pediatrics. Ukraine. 3(123): 80-84. doi 10.15574/SP.2022.123.80.
Статья поступила в редакцию 03.01.2022 г., принята в печать 18.04.2022 г.

Нейтропении часто встречаются в практике как врачей первичного звена, так и врачей-специалистов. Врожденные нейтропении являются редкими заболеваниями, они могут быть как изолированными самостоятельными заболеваниями, так и сопровождать ряд других врожденных ошибок иммунитета. Клиническое течение нейтропений может колебаться от бессимптомного при легкой форме до жизнеугрожающих инфекций при тяжелой форме. Лечение врожденных нейтропений до сих пор остается проблематичным. Наиболее распространенным и доступным методом лечения тяжелых врожденных нейтропений является гранулоцитарный колониестимулирующий фактор, хотя он кардинально не лечит заболевания и не предупреждает развития злокачественного преобразования. С другой стороны, использование гранулоцитарного колониестимулирующего фактора в правильно подобранных дозах позволяет улучшить клиническое течение болезни, качество жизни пациентов, избегать тяжелых септических осложнений. Трансплантация гемопоэтических стволовых клеток является эффективным методом лечения тяжелых врожденных нейтропений, не отвечающих на терапию гранулоцитарным фактором. Современные методы генетической коррекции открывают новые перспективы в лечении пациентов с тяжелыми врожденными нейтропениями.
Автор заявляет об отсутствии конфликта интересов.
Ключевые слова: врожденные нейтропении, лечение, гранулоцитарный колониестимулирующий фактор.
ЛИТЕРАТУРА

1. Badolato R, Fontana S, Notarangelo LD, Savoldi G. (2004). Congenital neutropenia: advances in diagnosis and treatment. Curr Opin Allergy Clin Immunol. 4 (6): 513-521. https://doi.org/10.1097/00130832-200412000-00007; PMid:15640692

2. Beaupain B, Leblanc T, Reman et al. (2009). Is pegfilgrastim safe and effective in congenital neutropenia? An analysis of the French Severe Chronic Neutropenia registry. Pediatr Blood Cancer. 53 (6): 1068-1073. https://doi.org/10.1002/pbc.22147; PMid:19618456

3. Bellanné-Chantelot C, Schmaltz-Panneau B, Marty C et al. (2018). Mutations in the SRP54 gene cause severe congenital neutropenia as well as Shwachman-Diamond-like syndrome. Blood. 132 (12): 1318-1331. https://doi.org/10.1182/blood-2017-12-820308; PMid:29914977 PMCid:PMC6536700

4. Berliner N, Horwitz M, Loughran TP. (2004). Congenital and acquired neutropenia. Hematology Am Soc Hematol Educ Program: 63-79. https://doi.org/10.1182/asheducation-2004.1.63; PMid:15561677

5. Boxer LA. (2012). How to approach neutropenia. Hematology Am Soc Hematol Educ Program: 174-182. https://doi.org/10.1182/asheducation.V2012.1.174.3798251; PMid:23233578

6. Boyarchuk O, Balatska N, Chornomydz I. (2019). Evaluation of warning signs of primary immunodeficiencies. Pediatria Polska — Polish Journal of Paediatrics. 94 (6): 337-341.

7. Boyarchuk O, Dmytrash L. (2019). Clinical Manifestations in the Patients with Primary Immunodeficiencies: Data from One Regional Center. Turkish Journal of Immunology. 7 (3): 113-119. https://doi.org/10.25002/tji.2019.1168

8. Boyarchuk O, Kinash M, Hariyan T, Bakalyuk T. (2019). Evaluation of knowledge about primary immunodeficiencies among postgraduate medical students. Archives of the Balkan Medical Union. 54 (1): 11-19. https://doi.org/10.31688/ABMU.2019.54.1.18

9. Boyarchuk O, Lewandowicz-Uszyńska A, Kinash M, Haliyash N, Sahal I, Kovalchuk T. (2018). Physicians' awareness concerning primary immunodeficiencies in the Ternopil Region of Ukraine. Pediatria Polska. 93 (3): 221-228. https://doi.org/10.5114/polp.2018.77435

10. Boyarchuk O, Volokha A, Hariyan T et al. (2019). The impact of combining educational program with the improving of infrastructure to diagnose on early detection of primary immunodeficiencies in children. Immunol Res. 67 (4-5): 390-397. https://doi.org/10.1007/s12026-019-09103-w; PMid:31713829

11. Boyarchuk O. (2021). Azithromycin and Co-Trimoxazole in Antimicrobial Prophylaxis: Special Emphasis on Primary Immunodeficiencies in Children. Bangladesh Journal of Medical Science. 20 (3): 530-538. https://doi.org/10.3329/bjms.v20i3.52794

12. Чернищова Л, Волоха A, Костюченко Л та ін. (2013). Дитяча імунологія. Київ: Медицина: 720.

13. Dale DC, Cottle TE, Fier CJ et al. (2003). Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. American Journal of Hematology. 72: 82-93. https://doi.org/10.1002/ajh.10255; PMid:12555210

14. Dale DC. (2017). How I manage children with neutropenia. Br J Haematol. 178 (3): 351-363. https://doi.org/10.1111/bjh.14677; PMid:28419427

15. Deordieva E, Shvets O, Voronin K et al. (2021). Nicotinamide (vitamin B3) treatment improves response to G-CSF in severe congenital neutropenia patients. Br J Haematol. 192 (4): 788-792. https://doi.org/10.1111/bjh.17313; PMid:33471934

16. Donadieu J, Beaupain B, Fenneteau O, Bellanné-Chantelot C. (2017). Congenital neutropenia in the era of genomics: classification, diagnosis, and natural history. Br J Haematol. 179 (4): 557-574. https://doi.org/10.1111/bjh.14887; PMid:28875503

17. Donadieu J, Beaupain B, Mahlaoui N, Bellanné-Chantelot C. (2013). Epidemiology of congenital neutropenia. Hematol Oncol Clin North Am. 27 (1): 1-17. https://doi.org/10.1016/j.hoc.2012.11.003; PMid:23351985

18. Fadeel B, Garwicz D, Carlsson G, Sandstedt B, Nordenskjöld M. (2021). Kostmann disease and other forms of severe congenital neutropenia. Acta Paediatr. 110 (11): 2912-2920. https://doi.org/10.1111/apa.16005; PMid:34160857

19. Fioredda F, Iacobelli S, van Biezen A et al. (2015). Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation. Blood. 126: 1885-1892. https://doi.org/10.1182/blood-2015-02-628859; PMid:26185129

20. Hariyan T, Kinash M, Kovalenko R, Boyarchuk O. (2020). Evaluation of awareness about primary immunodeficiencies among physicians before and after implementation of the educational program: A longitudinal study. PLoS One. 15 (5): e0233342. https://doi.org/10.1371/journal.pone.0233342; PMid:32470021 PMCid:PMC7259605

21. James RM, Kinsey SE. (2006). The investigation and management of chronic neutropenia in children. Arch Dis Child. 91 (10): 852-858. https://doi.org/10.1136/adc.2006.094706; PMid:16990357 PMCid:PMC2066017

22. Lebel A, Yacobovich J, Krasnov T et al. (2015). Genetic analysis and clinical picture of severe congenital neutropenia in Israel. Pediatric Blood and Cancer. 62: 103-108. https://doi.org/10.1002/pbc.25251; PMid:25284454

23. Link DC. (2019). Mechanisms of leukemic transformation in congenital neutropenia. Curr Opin Hematol. 26 (1): 34-40. https://doi.org/10.1097/MOH.0000000000000479; PMid:30431463 PMCid:PMC6447304

24. Makaryan V, Kelley ML, Fletcher B, Bolyard AA, Aprikyan AA, Dale DC. (2017). Elastase inhibitors as potential therapies for ELANE‐associated neutropenia. Journal of leukocyte biology. 102 (4): 1143-1151. https://doi.org/10.1189/jlb.5A1016-445R; PMid:28754797 PMCid:PMC5597518

25. Makaryan V, Zeidler C, Bolyard AA et al. (2015). The diversity of mutations and clinical outcomes for ELANE-associated neutropenia. Current Opinion in Hematology. 22: 3-11. https://doi.org/10.1097/MOH.0000000000000105; PMid:25427142 PMCid:PMC4380169

26. Morishima T, Watanabe K, Niwa A et al. (2014). Genetic correction of HAX1 in induced pluripotent stem cells from a patient with severe congenital neutropenia improves defective granulopoiesis. Haematologica. 99 (1): 19-27. https://doi.org/10.3324/haematol.2013.083873; PMid:23975175 PMCid:PMC4007926

27. Nasri M, Ritter M, Mir P et al. (2020). CRISPR/Cas9-mediated ELANE knockout enables neutrophilic maturation of primary hematopoietic stem and progenitor cells and induced pluripotent stem cells of severe congenital neutropenia patients. Haematologica. 105 (3): 598-609. https://doi.org/10.3324/haematol.2019.221804; PMid:31248972 PMCid:PMC7049355

28. Newburger PE, Dale DC. (2013). Evaluation and management of patients with isolated neutropenia. Seminars in hematology. 50 (3): 198-206. https://doi.org/10.1053/j.seminhematol.2013.06.010; PMid:23953336 PMCid:PMC3748385

29. Osone S, Imamura T, Fukushima-Nakase Y et al. (2016). Case reports of severe congenital neutropenia treated with unrelated cord blood transplantation with reduced-intensity conditioning. Journal of Pediatric Hematology-Oncology. 38: 49-52. https://doi.org/10.1097/MPH.0000000000000487; PMid:26599988

30. Rosenberg PS, Zeidler C, Bolyard AA et al. (2010). Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. British Journal of Haematology. 150: 196-199. https://doi.org/10.1111/j.1365-2141.2010.08216.x; PMid:20456363 PMCid:PMC2906693

31. Salehi T, Fazlollahi MR, Maddah M et al. (2012). Prevention and control of infections in patients with severe congenital neutropenia; a follow up study. Iran J Allergy Asthma Immunol. 11 (1): 51-56.

32. Skokowa J, Dale DC, Touw IP, Zeidler C, Welte K. (2017). Severe congenital neutropenias. Nat Rev Dis Primers. 3: 17032. https://doi.org/10.1038/nrdp.2017.32; PMid:28593997 PMCid:PMC5821468

33. Spoor J, Farajifard H, Rezaei N. (2019). Congenital neutropenia and primary immunodeficiency diseases. Crit Rev Oncol Hematol. 133: 149-162. https://doi.org/10.1016/j.critrevonc.2018.10.003; PMid:30661651

34. Tangye SG, Al-Herz W, Bousfiha A et al. (2020). Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 40 (1): 24-64. https://doi.org/10.1007/s10875-019-00737-x; PMid:31953710 PMCid:PMC7082301

35, Touw IP. (2022). Congenital neutropenia: disease models guiding new treatment strategies. Curr Opin Hematol. 29 (1): 27-33. https://doi.org/10.1097/MOH.0000000000000696; PMid:34854832 PMCid:PMC8654271

36. Tran NT, Graf R, Wulf-Goldenberg A et al. (2020). CRISPR-Cas9-Mediated ELANE Mutation Correction in Hematopoietic Stem and Progenitor Cells to Treat Severe Congenital Neutropenia. Mol Ther. 28 (12): 2621-2634. https://doi.org/10.1016/j.ymthe.2020.08.004; PMid:32822592 PMCid:PMC7704744

37. Tulpule A, Kelley JM, Lensch MW et al. (2013). Pluripotent stem cell models of Shwachman-Diamond syndrome reveal a common mechanism for pancreatic and hematopoietic dysfunction. Cell Stem Cell. 12 (6): 727-736. https://doi.org/10.1016/j.stem.2013.04.002; PMid:23602541 PMCid:PMC3755012

38. Walkovich K, Connelly JA. (2019). Congenital Neutropenia and Rare Functional Phagocyte Disorders in Children. Hematol Oncol Clin North Am. 33 (3): 533-551. https://doi.org/10.1016/j.hoc.2019.01.004; PMid:31030818